hVIVO (LON:HVO) Trading Down 44.4% - Time to Sell?

Shares of hVIVO plc (LON:HVO - Get Free Report) fell 44.4% on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 9 ($0.12). 81,223,922 shares traded hands during mid-day trading, an increase of 2,284% from the average session volume of 3,406,763 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analysts Set New Price Targets

Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a report on Friday.

hVIVO Stock Down 46.3%

The business has a 50 day moving average of GBX 16.16 and a two-hundred day moving average of GBX 18.13. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market capitalization of £61.56 million, a PE ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts predict that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Transactions at hVIVO

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,459.93). Company insiders own 14.03% of the company's stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.